Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0B3RL
|
|||
Former ID |
DIB014291
|
|||
Drug Name |
R-IFN-1a
|
|||
Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 2 | [1] | |
Company |
Merck-Serono Laboratories
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Interferon alpha/beta receptor 1 (IFNAR1) | Target Info | Modulator | [2] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
PI3K-Akt signaling pathway | ||||
Osteoclast differentiation | ||||
Toll-like receptor signaling pathway | ||||
Jak-STAT signaling pathway | ||||
Natural killer cell mediated cytotoxicity | ||||
Hepatitis C | ||||
Hepatitis B | ||||
Measles | ||||
Influenza A | ||||
Herpes simplex infection | ||||
NetPath Pathway | TCR Signaling Pathway | |||
Leptin Signaling Pathway | ||||
Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
Pathway Interaction Database | Downstream signaling in naï | |||
Reactome | Interferon alpha/beta signaling | |||
Regulation of IFNA signaling | ||||
WikiPathways | Toll-like receptor signaling pathway | |||
Interferon type I signaling pathways | ||||
Interferon alpha/beta signaling | ||||
Regulation of toll-like receptor signaling pathway | ||||
Osteoclast Signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. Br J Cancer. 1997;75(3):423-6. | |||
REF 2 | Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci.1999 Oct 15;168(2):131-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.